An open label study to evaluate the colesevelam HCL for accelerated elimination of teriflunomide, and monitoring of teriflunomide concentration using dried blood spot assay.

Trial Profile

An open label study to evaluate the colesevelam HCL for accelerated elimination of teriflunomide, and monitoring of teriflunomide concentration using dried blood spot assay.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs Colesevelam (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2017 Results published in the Journal of Clinical Pharmacology.
    • 21 Aug 2015 New trial record
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top